Company Announcements

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

Launch of new corporate brand and website to support strategic vision and accelerated growth ambitions

Company unveils a new visual identity, website, and commitment to innovation

London, UK, 1 September 2022: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), announces the launch of its new corporate brand and website.

The new corporate brand and website aligns with the Company's future vision and presents the significant transformation the Group has undergone, following new leadership and the successful launch of Accrufer® in the US. The new brand identity embodies the renewed sense of purpose, energy and enthusiasm of all its employees with a bright, progressive and dynamic feel representing a company that has transformed itself and is on a growth trajectory. Additionally, the new website provides key stakeholders, partners, and investors with a more modern and cleaner look and feel, making it easier to navigate and locate all up to date information and resources.

Greg Madison, Chief Executive Officer of Shield Therapeutics, said: "The launch of our new corporate brand and website is timely as we continue to make excellent progress by the 'new' Shield ethos and are pleased to offer our key stakeholders an updated website in order to learn more about our business, strategy and geographical markets that we are operating in. This is another step forward to help achieve our mission 'to improve lives together' and make Accrufer® the treatment of choice to treat iron deficiency."

For further information please contact:

About Accrufer®/Feraccru®

Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer®/Feraccru® has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: www.accrufer.com and www.feraccru.com

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.

Accrufer®/Feraccru® has patent coverage until the mid-2030s

Accrufer®/Feraccru® are registered trademarks of the Shield Group